Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Amit Kumar bought 5,000 shares of the company’s stock in a transaction that occurred on Thursday, March 25th. The stock was purchased at an average price of $4.86 per share, with a total value of $24,300.00. Following the transaction, the chief executive officer now directly owns 277,000 shares in the company, valued at $1,346,220. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Amit Kumar also recently made the following trade(s):
- On Friday, January 29th, Amit Kumar purchased 10,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.73 per share, for a total transaction of $37,300.00.
ANIX opened at $5.06 on Friday. The stock’s 50 day simple moving average is $5.30 and its 200 day simple moving average is $3.51. Anixa Biosciences, Inc. has a 1 year low of $1.33 and a 1 year high of $8.09. The firm has a market cap of $137.28 million, a price-to-earnings ratio of -11.00 and a beta of 1.58.
Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Thursday, January 7th. The company reported ($0.81) earnings per share for the quarter. On average, equities research analysts anticipate that Anixa Biosciences, Inc. will post -0.45 EPS for the current fiscal year.
A number of equities research analysts have recently issued reports on ANIX shares. Zacks Investment Research raised shares of Anixa Biosciences from a “strong sell” rating to a “hold” rating in a research note on Monday, March 15th. Aegis restated a “buy” rating on shares of Anixa Biosciences in a research report on Monday, February 15th.
A number of large investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in Anixa Biosciences during the 3rd quarter valued at $45,000. Bank of New York Mellon Corp increased its position in shares of Anixa Biosciences by 32.0% in the fourth quarter. Bank of New York Mellon Corp now owns 51,969 shares of the company’s stock valued at $160,000 after acquiring an additional 12,588 shares during the period. B. Riley Wealth Management Inc. purchased a new position in shares of Anixa Biosciences in the fourth quarter valued at about $37,000. Finally, BlackRock Inc. boosted its holdings in shares of Anixa Biosciences by 8.0% during the fourth quarter. BlackRock Inc. now owns 93,942 shares of the company’s stock worth $289,000 after purchasing an additional 6,964 shares during the period. Institutional investors own 7.68% of the company’s stock.
Anixa Biosciences Company Profile
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus.
Further Reading: Trading Options- What is a Strangle?
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.